42
GeneDx will face growing competition as the genomic diagnostics market attracts new entrants. However, its robust and expanding database —comprising over 850,000 sequenced exomes and genomes — alongside its proprietary interpretation engine, offers a durable competitive moat rooted in data science and scale.
The stock trades at a premium, reflecting its high-growth profile. Consensus EPS estimates of $1.48 for 2025 and $2.17 for 2026 imply P/E multiples of 73x and 42x, respectively. While these projections may prove conservative, such…